A Non-Interventional Study With Aromasin® As Adjuvant Treatment Of Invasive Early Breast Cancer
Status: TERMINATED
Study type: OBSERVATIONAL
Conditions: Invasive Early Breast Cancer
Interventions: DRUG: Aromasin
Sponsor: Pfizer